english.prescrire.org > Prescrire International > N°231 - November 2021

n°231

November 2021

Issue Contents
Editorial

Free  Words and numbers

p.255

New Products


Onasemnogene abeparvovec (Zolgensma°) in spinal muscular atrophy

p.257-258
Results that encourage continued evaluation

Editors' opinion. Acknowledging uncertainty

p.258

Covid-19 vaccine booster dose: great uncertainty over its value in the general population

p.258

Docetaxel (Taxotere° or other brands) and metastatic hormone-sensitive prostate cancer

p.259-260

Avapritinib (Ayvakyt°) and certain gastro­intestinal stromal tumours

p.260-261
Very weak data suggesting longer survival

INN Common stem: -fungin

p.261

Imipenem + cilastatin + relebactam (Recarbrio°) and serious infections

p.262-263

Nintedanib (Ofev°) in systemic sclerosis-associated interstitial lung disease

p.263

Adverse Effects


Known adverse effects of messenger RNA covid-19 vaccines as of mid-2021

p.264-265

Erenumab: hyper­­tension

p.266

Beta-blocker eye drops + verapamil: brady­cardia and collapse

p.266-267

Vasoconstrictor decongestants: ischaemic optic neuropathy

p.267

Free  Growth hormone: cardio­vascular events in young adults

p.268

Free  Thiazide diuretics: choroidal effusion and acute myo­­pia

p.268

Tramadol: hyper­­acusis

p.269

Prolonged treatment with topical or inhaled corticosteroids: osteoporotic fractures

p.269-270

Asthma and COPD: risk of confusion of the brand name of the drug with that of the inhaler

p.270

Reviews


Preventing the cardio­­vascular complications of type 2 diabetes

p.271
No advance with ertugliflozin

Canagliflozin and type 2 diabetes with nephr­o­pathy

p.271-272
As many risks as benefits?

Dapagliflozin and renal failure

p.272-273
Further evaluation needed

Outlook


Medical devices that resemble medicines: benefits for industry, uncertainties for patients

p.274-275

Ulipristal 5 mg (Esmya°) for uterine fibroids: authorisation reinstated in the EU

p.276

Free  Consultants on anything and everything

p.277

Accelerated marketing authorisation: many of the drugs approved do not have high therapeutic value

p.278

Book review. "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer"

p.279

Masthead


Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe